title: [High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
abstract: BACKGROUND
  Oral mucositis is a frequent complication, but is poorly studied among patients with solid tumors. The purpose of this study is to clarify the incidence rate of oral mucositis in Japanese breast cancer patients receiving anthracycline-based chemotherapy(FEC100).
  
  
  METHODS
  From June 2007 to July 2008, 61 breast cancer patients eligible for this study received anthracycline-based chemotherapy(FEC100: 5-FU 500mg/m / / 2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)at National Kyushu Cancer Center and Iwate Medical University Hospital. The incidence rate and grade of oral mucositis were evaluated in these patients.
  
  
  RESULTS
  The cumulative incidence of oral mucositis was about 50%. Episodes of oral mucositis were more common during courses with febrile neutropenia than during courses without it(75. 0% vs 44. 9%, p=0. 12). The reduction of oral mucositis was only 13. 6% after administering the steroidal ointment and/or mouthwash, including sodium azulene sulfonate.
  
  
  CONCLUSIONS
  New methods are needed to prevent and treat oral mucositis in patients receiving anthracycline- based chemotherapy(FEC100).
authors.affiliation: Dept. of Pharmacy, Fukuokahigashi Medical Center, Japan.
authors.forename: Mami
authors.initials: M
authors.lastname: Fukazawa
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Kawaguchi
authors.forename: Hideo
authors.initials: H
authors.lastname: Shigematsu
authors.forename: Chinami
authors.initials: C
authors.lastname: Koga
authors.forename: Emiko
authors.initials: E
authors.lastname: Mori
authors.forename: Sumiko
authors.initials: S
authors.lastname: Nishimura
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Seishi
authors.initials: S
authors.lastname: Satou
authors.forename: Kuniko
authors.initials: K
authors.lastname: Sawamura
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Kashiwaba
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use; D013280:Stomatitis / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D018943:Anthracyclines; D009067:Mouthwashes; D013256:Steroids; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil